Buscar
01/03/2026
Urinary glucose tetrasaccharide tracks disease activity in late-onset Pompe disease
Dominguez-González, C, Iannucci, D, Clark, J, Martin-Jiménez, P, Hold, S, Oliva, P, Bischinger, A, Gallardo, E, Diaz-Manera, J. Urinary glucose tetrasaccharide tracks disease activity in late-onset Pompe disease. NEUROMUSCULAR DISORDERS. 2026; 60DOI:10.1016/j.nmd.2026.106359. PMID:41638029. IF:2.800(Q2/5D).
01/02/2026
Challenges in myasthenia gravis diagnosis: an analysis of the diagnostic process of myasthenia gravis in a specialized clinic
Vesperinas, A, Rocaspana-Codana, J, Reyes-Leiva, D, Caballero-Avila, M, Carbayo, A, Collet-Vidiella, R, Llanso, L, Gallardo, E, Turon-Sans, J, Rojas-Garcia, R, Cortes-Vicente, E. Challenges in myasthenia gravis diagnosis: an analysis of the diagnostic process of myasthenia gravis in a specialized clinic. NEUROMUSCULAR DISORDERS. 2026; 59DOI:10.1016/j.nmd.2025.106284. PMID:41442860. IF:2.800(Q2/5D).
01/01/2026
E-Health & Innovation to Overcome Barriers in Neuromuscular Diseases. Report from the 3rd eNMD Congress: Pisa, Italy, 29-30 October 2021: Remote Monitoring: New Solutions for New Avenues in Neuromuscular Disorders
Schirinzi, E, Bochicchio, MA, Lochmüller, H, Vissing, J, Jordie-Diaz-Manerae, Evangelista, T, Plançon, JP, Fanucci, L, Marini, M, Tonacci, A, Mancuso, M, Segovia-Kueny, S, Toscano, A, Angelini, C, Schoser, B, Sacconi, S, Siciliano, G, e-NMD Grp. E-Health & Innovation to Overcome Barriers in Neuromuscular Diseases. Report from the 3rd eNMD Congress: Pisa, Italy, 29-30 October 2021: Remote Monitoring: New Solutions for New Avenues in Neuromuscular Disorders. Journal Of Neuromuscular Diseases. 2026; 13(1)DOI:10.3233/JND-230091. PMID:38728200. IF:3.400(Q2/3D).
01/01/2026
Efgartigimod as a treatment for people with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): a plain language summary of publication of the ADHERE trial
Allen, JA, Querol, L, Suresh, N, Remmerie, A, Mole, T, McCoy, K, Butler, L, van Hoorick, B, Kuwabara, S, van Doorn, PA, Lewis, RA. Efgartigimod as a treatment for people with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): a plain language summary of publication of the ADHERE trial. Therapeutic Advances in Neurological Disorders. 2026; 19DOI:10.1177/17562864251405202. PMID:41583073. IF:4.100(Q1/2D).
01/12/2025
ORGANIZATIONAL SUPPORT IN ADOPTING NEW TREATMENTS FOR GENERALIZED MYASTHENIA GRAVIS
Armangué, T, Gómez-Ballesteros, R, Querol, L, Gutiérrez-Gutiérrez, G, Sotoca, J, Luque, AA, Villaverde, R, Reyes, V, Salas, E, Diaz, P, Maurino, J, Cortés-Vicente, E. ORGANIZATIONAL SUPPORT IN ADOPTING NEW TREATMENTS FOR GENERALIZED MYASTHENIA GRAVIS. VALUE IN HEALTH. 2025; 28(12)DOI:. PMID:. IF:6.000(Q1/1D).
01/09/2025
HOW TO PROMOTE HEALTHY AND EQUITABLE RELATIONSHIPS IN FORMAL EDUCATION: THEORETICAL FRAMEWORK AND EDUCATIONAL PROPOSAL
Forcadell-Díez, L, Pérez, G, Fernández, A, Puig-Barrachina, V, Subirats, IG, Cortés, E, Moral, PD, Juárez, O. HOW TO PROMOTE HEALTHY AND EQUITABLE RELATIONSHIPS IN FORMAL EDUCATION: THEORETICAL FRAMEWORK AND EDUCATIONAL PROPOSAL. Gaceta Sanitaria. 2025; 39DOI:. PMID:. IF:1.500(Q3/7D).